33 results were returned
During 2016 and 2017 the complex litigation about part of AbbVie's patent portfolio protecting its Humira/adalimumab product drew attention in part because of the granting of a so-called Arrow declaration.
Europe’s biotech industry is more buoyant now than it’s ever been.
A combination of eager investors, the high-speed development of COVID-19 vaccines, exciting scientific developments and last year’s acceleration of ...
In a judgment handed down today the UK Supreme Court has upheld the appeal of Kymab who had challenged Regeneron's patents covering Kymab's 'Kymouse' transgenic mouse.
In the LexisNexis case analysis, Senior IP Associate, Will Smith, talks about the decision in the following matter: Neurim Pharmaceuticals (1991) Ltd & Anor v Generics UK Ltd (t\a MYLAN)  EWHC 3270 (Pat). This ...
The Intellectual Property Enterprise Court (IPEC) has held that a patent was invalid but also considered a possible defence to infringement by equivalence.
On 10 November 2017, Henry Carr J in the English Patents Court delivered a significant decision which will be of great interest to litigants in the field of generic pharmaceuticals.